Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
ASK1 mediates apoptotic cell death induced by genotoxic stress
The results indicate that the ASK1 pathway is involved in genotoxic stress-induced apoptosis and mediates apoptosis at a step upstream of caspase protease activation. Expand
Glyoxalase I is involved in resistance of human leukemia cells to antitumor agent-induced apoptosis.
Results indicate that glyoxalase I (GLO1) is a resistant factor to antitumor agent-induced apoptosis in human leukemia cells and that the GLO1 inhibitor could be a drug resistance-reversing agent. Expand
Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations.
JFCR39-DB is a useful tool to identify predictive biomarkers and to study the molecular pharmacology of the PI3K pathway in cancer, and correlations between the status of pathway members and the efficacy ofPI3K inhibitors are evaluated. Expand
Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR–ABL tyrosine kinase, CGP 57148
Results indicate that CGP 57148 shows apoptogenic and anti-proliferative effects on bcr–abl-positive cells by blocking BCR–ABL-initiated signaling pathways. Expand
AMF-26, a Novel Inhibitor of the Golgi System, Targeting ADP-ribosylation Factor 1 (Arf1) with Potential for Cancer Therapy*
- Y. Ohashi, H. Iijima, +7 authors T. Yamori
- Biology, Medicine
- The Journal of Biological Chemistry
- 9 December 2011
The data indicate that Arf1 activation is a promising target for cancer treatment, and AMF-26 is a novel anticancer drug candidate that inhibits the Golgi system, targeting Arf 1 activation. Expand
Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39.
It is found that ZSTK474 shares more in molecular targets with GDC-0941 than with either of the other two PI3K inhibitors, consistent with the biochemical assay result, and the biological implication of the difference in molecular target specificity of these PI3k inhibitors is under investigation. Expand
Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays
- N. Nakatsu, Y. Yoshida, +4 authors T. Yamori
- Biology, Medicine
- Molecular Cancer Therapeutics
- 1 March 2005
The results suggest that an integrated bioinformatical approach using chemos sensitivity and gene expression profiling is useful for the identification of genes determining chemosensitivity of cancer cells. Expand
Repression of cyclin B1 expression after treatment with adriamycin, but not cisplatin in human lung cancer A549 cells.
It is suggested that a reduction in cyclin B1 expression plays a role in the mechanism of action of certain anticancer drugs, including adriamycin, which induce G2 arrest in cancer cells. Expand
Search for novel anti-tumor agents from ridaifens using JFCR39, a panel of human cancer cell lines.
- Wen-zhi Guo, Yanwen Wang, Eri Umeda, Isamu Shiina, S. Dan, T. Yamori
- Chemistry, Medicine
- Biological & pharmaceutical bulletin
- 1 June 2013
Results indicate that RIDs-SB1 and RID-SB8 are interesting candidates for novel anti-cancer agents with unique modes of action. Expand
Ridaifen-SB8, a novel tamoxifen derivative, induces apoptosis via reactive oxygen species-dependent signaling pathway.
- Wen-zhi Guo, Isamu Shiina, +6 authors S. Dan
- Biology, Medicine
- Biochemical pharmacology
- 1 November 2013
It is concluded that RID-SB8 exerts an anticancer effect via a mode of action distinct from tamoxifen, and that RIDs could become a promising anticancer lead compound which selectively induces ROS formation and apoptosis in cancer cells. Expand